1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).
Affiliation
Department of Medical Oncology, University Hospital 12 De Octubre, Madrid, SpainHematology/Oncology, University of Pittsburgh, Pittsburgh, PAIssue Date
2016-04
Metadata
Show full item recordCitation
1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). 2016, 11 (4 Suppl):S153 J Thorac OncolJournal
Journal of Thoracic OncologyDOI
10.1016/S1556-0864(16)30326-4PubMed ID
27198355Type
ArticleLanguage
enISSN
1556-1380ae974a485f413a2113503eed53cd6c53
10.1016/S1556-0864(16)30326-4